Document is current
Any future updates will be listed below
-
Authors
McGowan, Barbara
Ciudin, Andreea https://orcid.org/0000-0001-5622-0203
Baker, Jennifer L. https://orcid.org/0000-0002-9649-6615
Busetto, Luca https://orcid.org/0000-0003-4883-8980
Dicker, Dror
Frühbeck, Gema https://orcid.org/0000-0002-8305-7154
Goossens, Gijs H. https://orcid.org/0000-0002-2092-3019
Monami, Matteo https://orcid.org/0000-0001-9349-828X
Sbraccia, Paolo
Martinez-Tellez, Borja
Woodward, Euan
Yumuk, Volkan
- License Information
-
More Information
Article History
Received: 14 April 2025
Accepted: 26 August 2025
First Online: 2 October 2025
Competing interests
: B.M. has received speaker and/or advisory fees from Novo Nordisk, Eli Lilly, AstraZeneca, Janssen, Pfizer and Merck Sharp & Dohme and a research grant from Novo Nordisk. B.M. is a shareholder of Reset Health. A.C. has received speaking fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Menarini and research grants from Eli Lilly, Novo Nordisk and Menarini. A.C. is also a member of the Data Monitoring Committee of Boehringer Ingelheim. J.L.B. has received a consulting fee and is an advisory board member for Novo Nordisk, with fees paid to her institution. L.B. has received payment of honoraria from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Pfizer, Bruno Farmaceutici, Regeneron, Rythm Pharmaceuticals and Pronokal as speaker and/or member of advisory boards. D.D. has received speaker and advisory board fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk and AstraZeneca and research grants from Eli Lilly, Novo Nordisk and Boehringer Ingelheim. G.F. has received payment of honoraria from Eli Lilly, Novo Nordisk, Regeneron and AstraZeneca as speaker and/or member of advisory boards and payment of honoraria as member of the OPEN Spain Initiative. G.H.G. has no relevant conflicts of interest to declare related to this article. M.M. has received speaking fees from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Sanofi and Novartis and research grants from Bristol Myers Squibb. P.S. received payment of honoraria and consulting fees from Boehringer Ingelheim, Chiesi, Novo Nordisk, Eli Lilly, Pfizer and Roche as a member of advisory boards. B.M.-T. has received grants from the EASO New Clinical Investigator Award 2024 and the EFSD Rising Star 2024, both supported by the Novo Nordisk Foundation. E.W. has no conflicts of interest to declare. V.Y. was engaged in advisory boards and lectures with Novo Nordisk, Eli Lilly, Rhythm and Regeneron.
